Marksans Pharma announced a fall in income in Q3 by 1.0% to Rs. 215.2 crore, a decline compared to the same quarter the previous year. Net profits also fell this quarter compared to last year's quarter, declining by over 31% to Rs. 12.8 crore. This is a sharp reversal from the momentum the company had seen in the past year.

The company is struggling with competition and price cuts in the UK and Europe markets, where revenues declined by over 35% in the nine months of FY17 compared to the previous year. Marksans Pharma is likely to now end FY17 with lower profits compared to FY16.